

Patent claims


1. Use of

a) 8-cyanoquinolone antibiotics or

b) quinolone antibiotics selected from the group consisting of: garenoxacin,
marbofloxacin, ibafloxacin, danofloxacin, difloxacin and orbifloxacin

for preparing medicaments for the systemic treatment of bacterial infections of the oral cavity.


2. Use according to Claim 1 of 8-cyanoquinolone antibiotics of the formula (I):



in which

X represents hydrogen, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, NH₂,

Y represents radicals of the structure



in which

R⁴ represents optionally hydroxyl- or methoxy-substituted straight-chain or branched C₁₋₄-alkyl, cyclopropyl, acyl having 1 to 3 carbon atoms,

R⁵ represents hydrogen, methyl, phenyl, thienyl or pyridyl,

R⁶ represents hydrogen or C₁₋₄-alkyl,

R⁷ represents hydrogen or C₁₋₄-alkyl,

R⁸ represents hydrogen or C₁₋₄-alkyl,

and

R¹ represents an alkyl radical having 1 to 3 carbon atoms, cyclopropyl, 2-fluoroethyl, methoxy, 4-fluorophenyl, 2,4-difluorophenyl or methylamino,

5 R² represents hydrogen or optionally methoxy- or 2-methoxyethoxy-substituted alkyl having 1 to 6 carbon atoms and also cyclohexyl, benzyl, 2-oxopropyl, phenacyl, ethoxycarbonylmethyl, pivaloyloxymethyl,

A represents =C(CN),

and their pharmaceutically acceptable salts and hydrates.

- 10 3. Use according to Claim 1 where the 8-cyanoquinolone antibiotic is Pradofloxacin.
4. Use according to Claim 1 for treating gingivitis, stomatitis, parodontitis and/or abscesses of the oral cavity.
5. Use according to Claim 1 where the disorders are mainly caused by bacteria of the group consisting of *Porphyromonas* spp., *Prevotella* spp., *Bacteroides* spp., *Actinobacillus*
- 15 *actinomycetemcomitans*, *Fusobacterium* spp., *Peptostreptococcus* spp., *Eikenella* *corrodens*, *Capnocytophaga* *ochracea*, *Campylobacter* *rectus*.